Boere, I., Pothuri, B., Sukhina, O., Myers, T., Tuninetti, V., Secord, A. A., … Cloven, N. (2024). 633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. In International Journal of Gynecological Cancer (Vol. 34, pp. A26–A28). Elsevier BV. https://doi.org/10.1136/ijgc-2024-esgo.33

Boere, Ingrid, Bhavana Pothuri, Olena Sukhina, Tashanna Myers, Valentina Tuninetti, Angeles Alvarez Secord, Florian Heitz, et al. “633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.” In International Journal of Gynecological Cancer, 34:A26–28. Elsevier BV, 2024. https://doi.org/10.1136/ijgc-2024-esgo.33.

Boere I, Pothuri B, Sukhina O, Myers T, Tuninetti V, Secord AA, et al. 633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. In: International Journal of Gynecological Cancer. Elsevier BV; 2024. p. A26–8.

Boere, Ingrid, et al. “633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.” International Journal of Gynecological Cancer, vol. 34, Elsevier BV, 2024, pp. A26–28. Crossref, doi:10.1136/ijgc-2024-esgo.33.

Boere I, Pothuri B, Sukhina O, Myers T, Tuninetti V, Secord AA, Heitz F, Nowicki P, Auranen A, Nevadunsky N, Gilbert L, Callahan MJ, Willmott L, Gold MA, Powell MA, Mccourt C, Vincent V, Simang V, Mirza MR, Cloven N. 633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. International Journal of Gynecological Cancer. Elsevier BV; 2024. p. A26–A28.